Mood and suicidality outcomes 3–11 years following pediatric anxiety disorder treatment
Authors:
- 8 May 2019
- journal article
- research article
- Published by Wiley in Depression and Anxiety
- Vol. 36 (10) , 930-940
Abstract
Youth anxiety interventions have potential to reduce risk for depression and suicidality. This naturalistic follow-up of the multi-site, comparative treatment trial, inking and behavior, and depressive symptoms 3-11 years (mean 6.25 years) following 12-week evidence-based youth anxiety treatment. Participants (N = 319; 10-26 years, mean 17 years) completed semiannual questionnaires and annual diagnostic interviews for 4 years. One-fifth (20.4%) of the sample met DSM-IV criteria for a mood disorder, 32.1% endorsed suicidal ideation, and 8.2% reported suicidal behavior. Latent class growth analysis yielded two linear trajectories of depressive symptoms, and 85% of the sample demonstrated a persistent low-symptom course over seven assessments. Child/Adolescent Anxiety Multimodal Study (CAMS) 12-week treatment outcome (positive response, remission) and treatment condition (cognitive behavior therapy [CBT], medication, CBT + medication, pill placebo) were not associated with subsequent mood disorder or suicidal thinking. CAMS remission predicted absence of suicidal behavior, and treatment response and remission predicted low depressive symptom trajectory. Greater baseline self-reported depressive symptoms predicted all long-term mood outcomes, and more negative life events predicted subsequent mood disorder, depressive symptom trajectory, and suicidal ideation. Effective early treatment of youth anxiety, including CBT, medication, or CBT + medication, reduces risk for subsequent chronic depressive symptoms and suicidal behavior. Attention to (sub)clinical depressive symptoms and management of negative life events may reduce odds of developing a mood disorder, chronic depressive symptoms, and suicidality. Findings contribute to evidence that early intervention for a primary disorder can serve as secondary prevention.Keywords
Funding Information
- National Institute of Mental Health (MH064089, MH064003, MH64107, MH64088, MH64092, MH063747)
This publication has 44 references indexed in Scilit:
- Impact of Treatments for Depression on Comorbid Anxiety, Attentional, and Behavioral Symptoms in Adolescents With Selective Serotonin Reuptake Inhibitor–Resistant DepressionJournal of the American Academy of Child & Adolescent Psychiatry, 2013
- Recovery and Recurrence Following Treatment for Adolescent Major DepressionArchives of General Psychiatry, 2011
- Remission after acute treatment in children and adolescents with anxiety disorders: Findings from the CAMS.Journal of Consulting and Clinical Psychology, 2011
- Lifetime Prevalence of Mental Disorders in U.S. Adolescents: Results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A)Journal of the American Academy of Child & Adolescent Psychiatry, 2010
- Treatment of Resistant Depression in Adolescents (TORDIA): Week 24 OutcomesAmerican Journal of Psychiatry, 2010
- Clinical characteristics of anxiety disordered youthJournal of Anxiety Disorders, 2010
- Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methodsChild and Adolescent Psychiatry and Mental Health, 2010
- The Treatment of Adolescent Suicide Attempters Study (TASA): Predictors of Suicidal Events in an Open Treatment TrialJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- Treatment of social anxiety with paroxetine: mediation of changes in anxiety and depression symptomsComprehensive Psychiatry, 2009
- Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood AnxietyNew England Journal of Medicine, 2008